<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02626130</url>
  </required_header>
  <id_info>
    <org_study_id>2013-0539</org_study_id>
    <secondary_id>13246</secondary_id>
    <secondary_id>15019972</secondary_id>
    <secondary_id>NCI-2016-00008</secondary_id>
    <nct_id>NCT02626130</nct_id>
  </id_info>
  <brief_title>Pilot Study of Presurgical Tremelimumab With or Without Cryoablation in Patients With Metastatic Renal Cell Carcinoma (RCC)</brief_title>
  <official_title>A Pilot Study of Tremelimumab With or Without Tissue Cryoablation in Patients With Metastatic Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Conquer Cancer Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to compare the safety and effectiveness of
      tremelimumab alone and in combination with cryoablation in patients with metastatic kidney
      cancer (clear cell or non clear cell type) having surgery. Researchers also want to learn how
      the combination may affect the immune system.

      Cryoablation is a procedure that uses a hollow, thin tube called a cryoprobe to freeze and
      destroy cancer tissue.

      This is an investigational study. Tremelimumab is not FDA approved or commercially available.
      Tremelimumab is currently being used for research purposes only.

      If you are in Arm B, the cryoablation system used for your cryoablation procedure has been
      FDA-approved for use in cancer. The use of this system for metastatic kidney cancer combined
      with tremelimumab is investigational.

      Up to 30 patients will take part in this study. All will be enrolled at MD Anderson.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Groups and Study Drug Administration:

      If you are found to be eligible to take part in this study, you will be randomly assigned (as
      in the flip of a coin) to 1 of 2 groups (called &quot;arms&quot;). Both you and the study staff will
      know which group you are in. You have an equal chance of being assigned to either group.

        -  If you are in Arm A, you will receive tremelimumab before and after surgery or biopsy.

        -  If you are in Arm B, you will have cryoablation and then receive tremelimumab before and
           after surgery or biopsy.

      All participants will receive tremelimumab by vein over about 60 minutes one time every 4
      weeks for your first 6 doses and then one time every 12 weeks after that.

      Cryoablation:

      If you are in Arm B, you will have cryoablation about 2-6 days before your first dose of
      study drug. To perform cryoablation, the affected area will first be numbed with anesthetic.
      Your study doctor will insert the cryoprobe needle and use an ultrasound device to help guide
      the cryoprobe until it reaches the cancerous area.

      When in place, the cryoprobe will be used to freeze the cancerous area. The doctor will be
      very careful to try to avoid damaging the surrounding normal tissue.

      The cryoablation procedure will last about 20 minutes. The cryoprobe will be removed when
      your doctor thinks the cancerous area has been treated as much as possible.

      There will be a small wound, like a puncture wound from a large needle. Most likely, you will
      not need any stitches to close this wound.

      Study Visits:

      Before each dose of tremelimumab, within 2 weeks before surgery or biopsy, within 4 weeks
      after surgery and every 4 weeks for 3 months after that:

        -  You will have a physical exam.

        -  Blood (about 5 tablespoons) will be drawn for routine tests, to measure your protein
           levels, to test your liver, kidney, and hormone function, to test for biomarkers, and to
           test your immune system.

      Every 2 weeks for the first 2 months of taking tremelimumab, blood (about 2-3 tablespoons)
      will be drawn for routine tests, to measure your protein levels, and to test your liver and
      kidney functions.

      Within 2 weeks before surgery, and within 4 weeks after surgery or biopsy, if the study
      doctor thinks it is needed, you will have the same imaging scans that you had at screening to
      check the status of the disease.

      Before each dose of tremelimumab beginning three (3) months after surgery or biopsy and every
      12 weeks after that:

        -  You will have a physical exam.

        -  Blood (about 5 tablespoons) will be drawn for routine tests, to measure your protein
           levels, to test your liver, kidney and hormone function, and to test your immune system.

      If the study doctor thinks it is needed, you will have the same imaging scans that you had at
      screening to check the status of the disease.

      Surgery or Biopsy:

      About 5 weeks after your second dose of tremelimumab, you will have surgery for kidney
      cancer. You will be asked to sign a separate consent form that describes the surgery and its
      risks. You may instead have a biopsy and you will be asked to sign a separate consent form
      that describes the biopsy and its risks.

      Length of Study:

      You may continue taking the study drug for as long as the doctor thinks it is in your best
      interest. You will no longer be able to take the study drug if the disease gets worse, if
      intolerable side effects occur, or if you are unable to follow study directions.

      Your active participation on the study will be over after the end-of-study visit.

      End-of-Study Visit:

      At about 30, 60, and 90 days after your last dose of study drug, you will return to the
      clinic for the following tests and procedures:

        -  You will have a physical exam.

        -  Blood (about 5 tablespoons) will be drawn for routine tests, to measure your protein
           levels, to test your liver, kidney and hormone function, to test for biomarkers, and to
           test your immune system.

        -  If the study doctor thinks it is needed, you will have the same imaging scans that you
           had at screening to check the status of the disease.

      Long-Term Follow-Up:

      A member of the study staff will contact you about every 6 months to ask about your health if
      the disease gets worse. This contact will be a phone call or by an e-mail. Your medical
      record may also be reviewed at that time. If you are contacted by phone, the call should last
      about 5 minutes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2016</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity of Presurgical Tremelimumab Alone and in Combination With Cryoablation, graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.</measure>
    <time_frame>3 months after surgery</time_frame>
    <description>Toxicities graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Extreme toxicities (TOX) defined as any grade 3 or higher adverse event that does not improve within 2 weeks of steroid therapy with the exception of asymptomatic endocrine events managed with hormone replacement therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>3 months after surgery</time_frame>
    <description>Objective response rate (ORR) defined as the number of subjects with a best response of complete response (CR) or partial response (PR) by irRC criteria divided by the number of randomized subjects.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Kidney Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A - Tremelimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive Tremelimumab at 10mg/kg every month for 2 doses prior to surgery, metastasectomy, or repeated biopsy. Cytoreductive surgery, metastasectomy, or repeated biopsy occurs 4-6 weeks after the 2nd dose of Tremelimumab. After 4 weeks post-surgery or biopsy, participants continue to receive anti-CTLA-4 every 4 weeks for 3 doses and every 12 weeks after that until progression.
Tremelimumab administered intravenously at a dose of 10 mg/kg. Participants receive first dose at Week 1, second dose at Week 5. After surgery participants receive one dose of Tremelimumab every 4 weeks for 3 doses and every 12 weeks after that until progression . All participants have their primary kidney tumor removed 4-6 weeks after the 2nd dose of Tremelimumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B - Cryoablation + Tremelimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive Tremelimumab at 10mg/kg every month for 2 doses prior to surgery, metastasectomy, or repeated biopsy. Cytoreductive surgery, metastasectomy, or repeated biopsy occurs 4-6 weeks after the 2nd dose of Tremelimumab. After 4 weeks post-surgery or biopsy, participants continue to receive anti-CTLA-4 every 4 weeks for 3 doses and every 12 weeks after that until progression.
Participants additionally receive cryoablation of a metastasis 2-6 days prior to the first dose of tremelimumab.
Participants receive first dose at Week 1, second dose at Week 5. After surgery participants receive one dose of investigational product every 4 weeks for 3 doses and every 12 weeks after that until progression. All participants have their primary kidney tumor removed 4-6 weeks after the 2nd dose of Tremelimumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tremelimumab</intervention_name>
    <description>Participants receive a course of 2 preoperative doses of Tremelimumab. Tremelimumab administered intravenously at a dose of 10 mg/kg. Participants receive first dose at Week 1, second dose at Week 5. After surgery participants receive one dose of Tremelimumab every 4 weeks for 3 doses and every 12 weeks after that until progression .</description>
    <arm_group_label>Arm A - Tremelimumab</arm_group_label>
    <arm_group_label>Arm B - Cryoablation + Tremelimumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cryoablation</intervention_name>
    <description>Participants have cryoablation procedure about 2-6 days before first dose of Tremelimumab. Study doctor inserts cryoprobe needle and an ultrasound device used to help guide cryoprobe until it reaches the cancerous area. When in place, cryoprobe used to freeze the cancerous area.</description>
    <arm_group_label>Arm B - Cryoablation + Tremelimumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Long-Term Follow-Up</intervention_name>
    <description>Participant contacted by study staff about every 6 months. Participant contacted by phone call or e-mail. Phone call should last about 5 minutes.</description>
    <arm_group_label>Arm A - Tremelimumab</arm_group_label>
    <arm_group_label>Arm B - Cryoablation + Tremelimumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients included in the study must be &gt;/= 18 years old.

          2. Metastatic renal cell carcinoma (clear cell or non clear cell). a.) One metastatic
             site amenable to cryoablation. b.)Patients with a single metastatic site may be
             enrolled if that site is amenable to ablation; however these patients will not be
             counted in secondary measures of response unless there is new disease detected during
             follow up. c.) Eligible for cytoreductive nephrectomy, metastasectomy, or repeated
             biopsy. Biopsy site cannot be lung, mediastinal lymph node, or bone (unless soft
             tissue component).

          3. Patients with any number of prior therapies with anti-angiogenic agents or
             immunotherapy with the exception of any previous anti-CTLA-4 directed agents are
             allowed. Ar 2 week washout period is required for all agents, except for bevacizumab
             where a 4 week washout is required.

          4. Performance status with ECOG score &lt;/= 2. Patients with performance status of 3 may be
             considered as long as the decline has been of short duration (&lt; 1 month), and is due
             to their malignancy and not a comorbid condition (example: pain limiting activity).

          5. Patient's with an International Metastatic renal cell carcinoma Database Consortium
             (IMDC or Heng) score of 3 or less will be included. Score greater than 4 will be
             excluded. 1 point each: requirement of systemic treatment for metastatic disease less
             than 1 year of original diagnosis of renal cell carcinoma, a serum calcium greater
             than 10, anemia, neutrophilia, thrombocytosis, ECOG performance status &gt;/= 2.

          6. No history of autoimmune disorders.

          7. Patients must have normal organ and marrow function as defined below: a) WBC &gt;/=
             2000/uL.; b) ANC &gt;/= 1000/uL.; c) Platelets &gt;/= 75 x 10^3/uL.; d) Hemoglobin &gt;/= 9
             g/dL.; e) Creatinine &lt;/= 3 x ULN.; f) ALT &lt;/= 3.0 x ULN for patients without liver
             metastases. For patients with liver metastasis ALT &lt;/= 5 x ULN is allowed.; g)
             Bilirubin &lt;/= 1.5 x ULN (except for patients with Gilbert's Syndrome, who must have a
             total bilirubin &lt;/= 3mg/dL).

          8. Ability to understand and willingness to sign a written informed consent document

          9. Females of childbearing potential who are sexually active with a non-sterilized male
             partner and non-sterilized males must use a highly effective method of contraception
             for 28 days prior to the first dose of investigational product, and must agree to
             continue using such precautions for 180 days after the final dose of investigational
             product; cessation of contraception after this point should be discussed with a
             responsible physician. Periodic abstinence, the rhythm method, and the withdrawal
             method are not acceptable methods of contraception. They must also refrain from egg
             cell donation for 180 days after the final dose of investigational product; a) Females
             of childbearing potential are defined as those who are not surgically sterile (ie,
             bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or
             postmenopausal (defined as 12 months with no menses without an alternative medical
             cause);

         10. (Exclusion #8 Continued): b) A highly effective method of contraception is defined as
             one that results in a low failure rate (ie, less than 1% per year) when used
             consistently and correctly. The acceptable methods of contraception are: Barrier
             Method (e.g. male condom with spermicide, copper T intrauterine device, or
             levonorgestrel-releasing intrauterine system - MirenaÂ®) or Hormonal Methods (e.g.
             implants, hormone shot or injection, combined pill, minipill, or patch).

        Exclusion Criteria:

          1. Unresolved toxicities from prior anticancer therapy, defined as having not resolved to
             NCI CTCAE v4.03 Grade 0 or 1 with the exception of alopecia and laboratory values
             listed per the inclusion criteria.

          2. Known or suspected autoimmune disease. Patients with a history of inflammatory bowel
             disease (including Crohn's disease and ulcerative colitis) and autoimmune disorders
             such as rheumatoid arthritis, systemic progressive sclerosis [scleroderma], Systemic
             Lupus Erythematosus or autoimmune vasculitis [e.g., Wegener's Granulomatosis] are
             excluded from this study. Patients with a history of Hashimoto's thyroiditis only
             requiring hormone replacement, Type I diabetes, or psoriasis not requiring systemic
             treatment, or conditions not expected to recur in the absence of an external trigger
             are allowed to participate.

          3. Any condition requiring systemic treatment with corticosteroids (&gt;10mg daily
             prednisone equivalents) or other immunosuppressive medications within 14 days prior to
             first dose of study drug. Inhaled steroids and adrenal replacement steroids doses
             &gt;10mg daily prednisone equivalents are permitted in the absence of active autoimmune
             disease.

          4. Autoimmune disease: Patients with a history of inflammatory bowel disease (including
             Crohn's disease and ulcerative colitis) and autoimmune disorders such as rheumatoid
             arthritis, systemic progressive sclerosis [scleroderma], Systemic Lupus Erythematosus
             or autoimmune vasculitis [e.g., Wegener's Granulomatosis] are excluded from this
             study.

          5. Any underlying medical or psychiatric condition, which in the opinion of the
             Investigator, will make the administration of study drug hazardous or obscure the
             interpretation of AEs, such as a condition associated with frequent diarrhea.

          6. Patients with untreated brain metastases.

          7. Major surgery within 4 weeks of enrollment

          8. History of other malignancies, other than non-melanoma skin cancer, Ta or T1 (low
             grade) bladder carcinomas, or other low grade cancer of very low clinical impact,
             unless in complete remission and off therapy for that disease for at least 2 years.

          9. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, history of congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

         10. Known HIV, Hepatitis B, or Hepatitis C.

         11. Untreated symptomatic spinal cord compressions.

         12. Any non-oncology live or attenuated vaccine therapy used for prevention of infectious
             diseases within 30 days prior to the first dose of tremelimumab; if patients is
             enrolled, patient should not receive live vaccine during the study and 180 days after
             the last dose of tremelimumab.

         13. Concomitant therapy with any of the following: IL-2, interferon or other non-study
             immunotherapy regimens; cytotoxic chemotherapy; immunosuppressive agents; other
             investigation therapies; or chronic use of systemic corticosteroids (used in the
             management of cancer or non-cancer-related illnesses).

         14. Previous participation in tremelimumab or ipilimumab clinical trial or prior treatment
             with a CD137 agonist or CTLA-4 inhibitor or agonist.

         15. Female subjects who are pregnant, breast-feeding or male or female patients of
             reproductive potential who are not employing an effective method of birth control from
             screening to 90 days after the last dose of tremelimumab monotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Padmanee Sharma, MD,PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Padmanee Sharma, MD,PHD</last_name>
    <phone>713-563-1602</phone>
  </overall_contact>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2015</study_first_submitted>
  <study_first_submitted_qc>December 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2015</study_first_posted>
  <last_update_submitted>March 12, 2018</last_update_submitted>
  <last_update_submitted_qc>March 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney Cancer</keyword>
  <keyword>Tremelimumab</keyword>
  <keyword>Cryoablation</keyword>
  <keyword>Cryoprobe</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tremelimumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

